Back to Authors

Schwarzschild, Michael A.

https://orcid.org/0000-0001-6019-8280

Mayo Clinic

Massachusetts General Hospital

Citations 5

Effect of Urate-Elevating Inosine on Early Parkinson Disease Progression
Investigators, The Parkinson Study Group SURE-PD3, Bluett, Brent , Togasaki, Daniel M., Mihaila, Dragos, Evatt, Marian L., Rezak, Michael, Jain, Samay , Schwarzschild, Michael A. , Ascherio, Alberto, Casaceli, Cindy, Kamp, Cornelia , Lungu, Codrin , Oakes, David , Rudolph, Alice, Shoulson, Ira , Scott, B.L. , Gauger, Lisa, Aldred, Jason , Bixby, Melissa, Ciccarello, Jill, Gunzler, Steven A. , Henchcliffe, Claire , Brodsky, Matthew , Keith, Kellie, Hauser, Robert A. , LeDoux, Mark S. , Hinson, Vanessa K. , Kumar, Rajeev , Hunter, Christine , Christine, Chadwick W. , Daley, Aaron, Leehey, Maureen A. , Marcaida, Joy Antonelle de, Hung, Albert Y. , Bwala, Grace, Simon, David K. , Simuni, Tanya , Poon, Cynthia , Schiess, Mya C. , Park, Ariane , Peterson, Carolyn, Criswell, Susan R. , Durphy, Jennifer, Shill, Holly A. , Mehta, Shyamal H. , Deik, Andres , Fang, John Y., Stover, Natividad , Zhang, Lin , Dewey, Richard B. , Gerald, Ashley, Boyd, James T. , Houston, Emily , Suski, Valerie, Mosovsky, Sherri, Cloud, Leslie , Shah, Binit, James, Raymond , Zauber, S. Elizabeth , Reich, Stephen G. , Langhammer, April, LaFaver, Kathrin , Kaminski, Patricia L. , Goudreau, John L. , Russell, Doozie, Houghton, David , LaRoche, Ashley , Thomas, Karen , McGraw, Martha, Mari, Zoltan, Blindauer, Karen, Rabin, Marcie, Kurlan, Roger, Morgan, John C. , Ainslie, Melissa, Bódis-Wollner, Iván , Waters, Cheryl , Ratel, Amber Servi, Beck, Christopher A. , Bolger, Patrick, Callahan, Katherine F., Crotty, Grace F. , Klements, David , Kostrzebski, Melissa, McMahon, Gearoid M. , Pothier, Lindsay , Hauser, Robert A , Simuni, Tanya , Investigators, The Parkinson Study Group SURE-PD3, Curhan, Gary C. , Fitzgerald, Rebecca, Macklin, Eric A. , Marek, Kenneth , Mozaffarian, Dariush , Videnovic, Aleksandar , Goetz, Christopher G. , Espay, Alberto J. , Jimenez‐Shahed, Joohi , Friedman, Joseph H. , Litvan, Irene , Chou, Kelvin L. , Bhatti, Danish , Rosenthal, Liana S. , Ahmed, Anwar E. , Saint‐Hilaire, Marie , Shprecher, David , Pahwa, Rajesh , LeWitt, Peter A. , Kaminski, Patricia, Thomas, Karen, Serrano, Carmen , Soileau, Michael J , Schneider, Ruth B. , Waikar, Sushrut S. , Lang, Anthony E. , Mestre, Tiago

JAMA | September 14, 2021 | Volume: 326 | Issue: 10 | Pages: 926

10.1001/jama.2021.10207 Get It

Melanocortin 1 Receptor Activation Protects Against Alpha-Synuclein Pathologies in Models of Parkinson’s Disease
Cai, Waijiao , Feng, Danielle, Lin, Yue, Xu, Yuehang, McLean, Pamela J. , Frosch, Matthew P. , Fisher, David E. , Schwarzschild, Michael A. , Chen, Xiqun , McLean, Pamela J , Vanderburg, Charles R.

No container title available | March 17, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-286792/v1 Get It

Abstract Background: Epidemiological studies suggest a link between the melanoma-related pigmentation gene melanocortin 1 receptor ( MC1R ) and risk of Parkinson disease (PD). We previously showed that MC1R signaling can facilitate nigrostriatal dopaminergic neuron survival. The present study investigates the neuroprotective potential of MC1R against neurotoxicity induced by alpha-synuclein (αSyn), a key player in PD genetics and pathogenesis. Methods: Nigral dopaminergic neuron toxicity induced by local overexpression of aSyn was assessed in mice that had an inactivating mutation of MC1R , overexpressed its wild-type transgene, or were treated with MC1R agonists. The role of nuclear factor erythroid 2-related factor 2 (Nrf2) in MC1R-mediated protection against αSyn was characterized in vitro . Furthermore, MC1R expression was determined in human postmortem midbrains from patients with PD and unaffected subjects. Results: Targeted expression of αSyn in the nigrostriatal pathway induced exacerbated synuclein pathologies in MC1R mutant mice, which were accompanied by neuroinflammation and altered Nrf2 responses, and reversed by the human MC1R transgene. Two MC1R agonists were neuroprotective against αSyn-induced dopaminergic neurotoxicity. In vitro experiments showed that Nrf2 was a necessary mediator of MC1R effects. Lastly, MC1R was present in dopaminergic neurons in the human substantia nigra and appeared to be reduced in PD patients. Conclusion: Our study supports an interaction between MC1R and αSyn that can be mediated by neuronal MC1R through Nrf2. It provides evidence for MC1R as a therapeutic target and a rationale for development of MC1R-activating strategies for PD.
Activity enhances dopaminergic long-duration response in Parkinson disease
Kang, Un Jung , Auinger, Peggy , Fahn, Stanley, Oakes, David , Shoulson, Ira , Kieburtz, Karl, Rudolph, Alice, Seibyl, John , Olanow, C. Warren , Tanner, Caroline M., Schifitto, Giovanni , Zhao, Hongwei , Reyes, Lydia, Shinaman, Aileen, Comella, Cynthia L., Blasucci, Lucia M., Samanta, Johan, Stacy, Mark, Williamson, Kelli, Harrigan, Mary, Greene, Paul, Ford, Blair, Moskowitz, Carol, Truong, Daniel , Pathak, Mayank , Jankovic, Joseph, Ondo, William G. , Atassi, Farah, Hunter, Christine , Jacques, Carol, Lannon, Margaret C., Russell, David , Jennings, Danna , Fussell, B., Schwarzschild, Michael A. , Growdon, John H., Tennis, Marsha, Gauthier, Serge , Panisset, Michel , Hall, Jean, Gancher, Stephen T., Hammerstad, John P., Stone, Claudia, Alexander-Brown, Barbara, Molho, Eric , Brown, Diane, Evans, Sharon, Manyam, Bala V., Simpson, Patricia , Wulbrecht, Brian, Whetteckey, Jacqueline, Roberts, Ted E, King, Pamela, Zesiewicz, Theresa A. , Gauger, Lisa, Trugman, Joel M. , Wooten, G. Frederick, Rost‐Ruffner, Elke, Suchowersky, Oksana , Ranawaya, Ranjit, Wood, Susan M. , Pantella, Carol , Kurlan, Roger, Richard, Irene Hegeman, Pearson, N. Shirlene, Caviness, John N., Adler, Charles, Lind, Marlene, Siderowf, Andrew , Colcher, Amy, Lloyd, Mary, Weiner, William J., Shulman, Lisa M. , Koller, William C., Lyons, Kelly , Feldman, Robert G., Ellias, Samuel A., Thomas, Cathi-Ann, Juncos, Jorge L., Watts, Ray L., Partlow, Anna, Tetrud, James W., Togasaki, Daniel M., Stewart, Tracy, Mark, Margery H., Sage, Jacob I., Caputo, Debbie, Gould, Harry J. , Rao, Jayaraman, McKendrick, A. D., Brin, Mitchell F. , Danisi, Fabio , Benabou, Reina, Hubble, Jean, Paulson, George W., Reider, Carson, Birnbaum, Alex, So, Julie , Dubinsky, Richard , Uitti, Ryan J. , Turk, Margaret F., Rottenberg, David A., Hansen, Joy, Ramos, Serrano, Waters, Cheryl , Lew, Mark, Welsh, Mickie, Kawai, Connie, OʼBrien, Christopher , Kumar, Rajeev , Seeberger, Lauren , Judd, Deborah, Mendis, Tilak, Grimes, David A. , Sutherland, Laura, Dawson, Ted M. , Reich, Stephen G. , Frey, Kirk A. , Wernette, K., Marek, Kenneth , Lang, Anthony E. , Goetz, Christopher G. , Jankovic, Joseph, Friedman, Joseph H. , Standaert, David G. , Factor, Stewart Alan , Clark, Jeffrey N. , Martin, W. R. Wayne , Hauser, Robert A. , Perlmutter, Joel S. , Racette, Brad A. , Simuni, Tanya , Saint‐Hilaire, Marie , Miyasaki, Janis M. , Johnston, Lisa , Pahwa, Rajesh , Wszołek, Zbigniew K. , Tuite, Paul , Barclay, Corlane , Dunlop, Rebecca A. , Albin, Roger L.

Neurology | March 30, 2012 | Volume: 78 | Issue: 15 | Pages: 1146-1149

10.1212/wnl.0b013e31824f8056 Get It

Meeting Report: Consensus Statement—Parkinson’s Disease and the Environment: Collaborative on Health and the Environment and Parkinson’s Action Network (CHE PAN) Conference 26–28 June 2007
Bronstein, Jeff M. , Carvey, Paul M., Chen, Honglei , Cory‐Slechta, Deborah A. , Monte, Donato A. Di , Duda, John E. , English, Paul , Goldman, Samuel M. , Grate, Stephen J., Hoppin, Jane A. , Jewell, Sarah A. , Kamel, Freya , Langston, J. William, Logroscino, Giancarlo , Nelson, Lorene M. , Ravina, Bernard, Rocca, Walter A. , Ross, G. Webster, Schettler, Ted, Schwarzschild, Michael A. , Scott, Bill, Seegal, Richard F., Singleton, Andrew , Steenland, Kyle , Eeden, Stephen Van Den, Weisskopf, Marc G. , Hansen, Johnni , Koroshetz, Walter J. , Tanner, Caroline M. , Logroscino, Giancarlo

Environmental Health Perspectives | August 25, 2008 | Volume: 117 | Issue: 1 | Pages: 117-121

10.1289/ehp.11702 Get It

Abstract Background Parkinson’s disease (PD) is the second most common neurodegenerative disorder. People with PD, their families, scientists, health care providers, and the general public are increasingly interested in identifying environmental contributors to PD risk. Methods In June 2007, a multidisciplinary group of experts gathered in Sunnyvale, California, USA, to assess what is known about the contribution of environmental factors to PD. Results We describe the conclusions around which they came to consensus with respect to environmental contributors to PD risk. We conclude with a brief summary of research needs. Conclusions PD is a complex disorder, and multiple different pathogenic pathways and mechanisms can ultimately lead to PD. Within the individual there are many determinants of PD risk, and within populations, the causes of PD are heterogeneous. Although rare recognized genetic mutations are sufficient to cause PD, these account for < 10% of PD in the U.S. population, and incomplete penetrance suggests that environmental factors may be involved. Indeed, interplay among environmental factors and genetic makeup likely influences the risk of developing PD. There is a need for further understanding of how risk factors interact, and studying PD is likely to increase understanding of other neurodegenerative disorders.